<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Nexalin Technology Inc. — News on 6ix</title>
    <link>https://6ix.com/company/nexalin-technology-inc</link>
    <description>Latest news and press releases for Nexalin Technology Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 28 Apr 2026 13:15:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/nexalin-technology-inc" rel="self" type="application/rss+xml" />
    <item>
      <title>Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects  and Clinical Improvement in Chronic Insomnia</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-announces-peer-reviewed-publication-with-neuroimaging-data-in-psychotherapy-and-psychosomatics-highlighting-brain-network-effects-and-clinical-improvement-in-chronic-insomnia</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-announces-peer-reviewed-publication-with-neuroimaging-data-in-psychotherapy-and-psychosomatics-highlighting-brain-network-effects-and-clinical-improvement-in-chronic-insomnia</guid>
      <pubDate>Tue, 28 Apr 2026 13:15:00 GMT</pubDate>
      <description>Publication reports statistically significant improvement in sleep quality following treatment with Nexalin’s 15 mA, 77.5 Hz stimulation approach, with no meaningful improvement in the sham group Neuroimaging data provides mechanistic support for Nexalin’s proprietary DIFS™ technology and further validates the Company’s advanced non-pharmacologic treatment strategy for mental health issues Houston, TX, April 28, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “N</description>
    </item>
    <item>
      <title>Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-advances-pivotal-clinical-trial-of-halotm-clarity-toward-q2-2026-enrollment</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-advances-pivotal-clinical-trial-of-halotm-clarity-toward-q2-2026-enrollment</guid>
      <pubDate>Wed, 22 Apr 2026 13:35:00 GMT</pubDate>
      <description>160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submission for moderate-to-severe insomniaHOUSTON, TX, April 22, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced it has entered into agreements to advance its planned pivotal clinical trial evaluating the HALO™ Clarity device for the treatment of moderat</description>
    </item>
    <item>
      <title>Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-advances-fda-alzheimers-strategy-following-landmark-leadership-meetings-in-the-us-and-china</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-advances-fda-alzheimers-strategy-following-landmark-leadership-meetings-in-the-us-and-china</guid>
      <pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
      <description>Company Designing FDA Application Amendments and U.S. Clinical Strategy Leveraging Extensive Real-World Neurostimulation Data Sets Reflecting Broad Clinical</description>
    </item>
    <item>
      <title>Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-announces-peer-reviewed-study-showing-the-companys-difstm-technology-reduced-self-injury-and-depression-symptoms-in-female-adolescents</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-announces-peer-reviewed-study-showing-the-companys-difstm-technology-reduced-self-injury-and-depression-symptoms-in-female-adolescents</guid>
      <pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
      <description>BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and depressive symptoms, with brain-network findings further</description>
    </item>
    <item>
      <title>Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-announces-pivotal-halotm-clarity-trial-to-support-planned-de-novo-fda-submission-targeting-multi-billion-dollar-insomnia-market</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-announces-pivotal-halotm-clarity-trial-to-support-planned-de-novo-fda-submission-targeting-multi-billion-dollar-insomnia-market</guid>
      <pubDate>Tue, 24 Feb 2026 13:07:00 GMT</pubDate>
      <description>150-Patient, Triple-Blinded, Sham-Controlled Study Designed to be Executed in Collaboration with Lindus Health to Support Future FDA Submission for Drug-Free Insomnia Treatment Builds on Prior Peer-Reviewed Clinical Data and International Regulatory Approvals HOUSTON, TX, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced continued advancement toward its</description>
    </item>
    <item>
      <title>Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-participates-in-and-commends-recent-congressional-momentum-supporting-deep-brain-neurostimulation-research-for-veterans-and-neurological-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-participates-in-and-commends-recent-congressional-momentum-supporting-deep-brain-neurostimulation-research-for-veterans-and-neurological-disorders</guid>
      <pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
      <description>Multiple new federal actions highlight deep brain neurostimulation as a high-priority emerging therapy for TBI, PTSD, stroke recovery, and Alzheimer’s disease</description>
    </item>
    <item>
      <title>Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI &amp; PTSD Care</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-launches-neurocare-ai-driven-133700196</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-launches-neurocare-ai-driven-133700196</guid>
      <pubDate>Thu, 05 Feb 2026 13:37:00 GMT</pubDate>
      <description>New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health disordersHOUSTON, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the launch of its new AI-designed virtual clinic platform, NeuroCare®,</description>
    </item>
    <item>
      <title>Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-highlights-expanding-body-peer-134500662</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-highlights-expanding-body-peer-134500662</guid>
      <pubDate>Mon, 02 Feb 2026 13:45:00 GMT</pubDate>
      <description>Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation TechniquesHOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation te</description>
    </item>
    <item>
      <title>Nexalin Technology Receives Nasdaq Listing Status Notification</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-receives-nasdaq-listing-221500506</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-receives-nasdaq-listing-221500506</guid>
      <pubDate>Fri, 23 Jan 2026 22:15:00 GMT</pubDate>
      <description>HOUSTON, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has received a notification letter (the &quot;Notification Letter&quot;) from the Nasdaq Stock Market LLC (the &quot;NASDAQ&quot;) dated January 21, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement as set forth under NASDAQ Listing Rule 5550(a)</description>
    </item>
    <item>
      <title>Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/published-peer-reviewed-study-demonstrates-140000667</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/published-peer-reviewed-study-demonstrates-140000667</guid>
      <pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
      <description>Four weeks of non-invasive DIFS™ neurostimulation delivers meaningful attention gains alongside objective brain imaging changesHOUSTON, TX, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of a new peer-reviewed clinical study in Molecular Psychiatry demonstrating Nexalin’s Deep Intracranial Frequency Stimulation (DIFS™) te</description>
    </item>
    <item>
      <title>Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-completes-fda-q-130000147</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-completes-fda-q-130000147</guid>
      <pubDate>Wed, 03 Dec 2025 13:00:00 GMT</pubDate>
      <description>FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s diseaseHOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the successful completion of a substantive Q-Submission (“Q-Sub”) meeting with the U.S. Food and Drug Administration (“FDA”)</description>
    </item>
    <item>
      <title>Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&amp;A Session on December 4</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/join-nexalin-technology-exclusive-live-130000980</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/join-nexalin-technology-exclusive-live-130000980</guid>
      <pubDate>Tue, 02 Dec 2025 13:00:00 GMT</pubDate>
      <description>HOUSTON, TX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL) is pleased to invite investors to a webinar on December 4, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin’s CEO Mark White, who will provide an inside look at Nexalin’s game-changing approach to mental healthcare through its proprietary, non-invasive Deep Intracranial Frequency Stimulation (DIFS™) technology. White will detail the Compa</description>
    </item>
    <item>
      <title>Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-15-milliamp-neurostimulation-device-140000352</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-15-milliamp-neurostimulation-device-140000352</guid>
      <pubDate>Tue, 18 Nov 2025 14:00:00 GMT</pubDate>
      <description>Peer-reviewed case report published in The American Journal on Addictions highlights significant clinical improvement and sustained abstinence following Nexalin’s non-invasive therapyHOUSTON, TX, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of an independent, peer-reviewed study in The American Journal on Addictions titled “High-int</description>
    </item>
    <item>
      <title>Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-appoints-carmi-masha-141500155</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-appoints-carmi-masha-141500155</guid>
      <pubDate>Thu, 13 Nov 2025 14:15:00 GMT</pubDate>
      <description>Appointment Follows Israeli Ministry of Health Approval for Nexalin’s Gen-2 SYNC DeviceHOUSTON, TX, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that it has entered into an exclusive distribution agreement with Carmi Masha Technologies Ltd. (“Carmi Masha”), a leading Israeli medical device distributor, to market and sell Nexalin’s Gen-2 Console (“S</description>
    </item>
    <item>
      <title>Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-q-submission-gen-133000680</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-q-submission-gen-133000680</guid>
      <pubDate>Wed, 05 Nov 2025 13:30:00 GMT</pubDate>
      <description>This strategic filing with the FDA follows encouraging internal data and recent published studies supporting Nexalin’s frequency neurostimulator as a potential non-invasive therapy for cognitive disorders associated with Alzheimer’s diseaseHOUSTON, TX, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the U.S. Food and Drug Administration (“FDA”) h</description>
    </item>
    <item>
      <title>Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-announces-regulatory-approval-123000939</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-announces-regulatory-approval-123000939</guid>
      <pubDate>Thu, 30 Oct 2025 12:30:00 GMT</pubDate>
      <description>HOUSTON, TX, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that its Gen-2 Console (“SYNC”), 15 milliamp (mA) neurostimulation device has been granted regulatory approval for sale in Israel by the Israeli Ministry of Health. Mark White, CEO of Nexalin Technology, stated, “We are extremely proud to have received regulatory clearance in Israel, which i</description>
    </item>
    <item>
      <title>Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-difs-neurostimulation-shows-cognitive-130000018</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-difs-neurostimulation-shows-cognitive-130000018</guid>
      <pubDate>Tue, 21 Oct 2025 13:00:00 GMT</pubDate>
      <description>Three Independent Studies Published in “Alzheimer’s Research &amp; Therapy,” “Journal of Alzheimer’s Disease,” and “Radiology” Validate Nexalin’s Non-Invasive Approach with Consistent Cognitive and Neuroimaging BenefitsHOUSTON, TX, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that three independently published, peer-reviewed clinical studies, coupled w</description>
    </item>
    <item>
      <title>Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-expands-scientific-advisory-123000075</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-expands-scientific-advisory-123000075</guid>
      <pubDate>Mon, 13 Oct 2025 12:30:00 GMT</pubDate>
      <description>HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the appointment of Dr. Robert Rothstein, a pioneering expert in mental healthcare, to its Scientific Advisory Board (SAB). This addition reinforces Nexalin’s strategic focus on the global mental healthcare crisis, including the treatment of Alzheimer’s disease and Traumatic Brain Inju</description>
    </item>
    <item>
      <title>Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-announces-attendance-2025-120000145</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-announces-attendance-2025-120000145</guid>
      <pubDate>Fri, 10 Oct 2025 12:00:00 GMT</pubDate>
      <description>HOUSTON, TX, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is excited to announce its participation in the upcoming 2025 Maxim Growth Summit on October 22nd at The Hard Rock Hotel NYC. This event brings together industry experts, innovators, and thought leaders to explore the latest trends and advancements across several industries. Attendees will have the o</description>
    </item>
    <item>
      <title>Nexalin Technology Announces Additional Positive Clinical Results in Alzheimer’s Disease with Gen-2 SYNC Neurostimulation Device</title>
      <link>https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-announces-additional-positive-123000873</link>
      <guid isPermaLink="true">https://6ix.com/company/nexalin-technology-inc/news/nexalin-technology-announces-additional-positive-123000873</guid>
      <pubDate>Wed, 08 Oct 2025 12:30:00 GMT</pubDate>
      <description>40-Hz DIFS™ significantly improves cognitive performance and brain connectivity in peer-reviewed clinical trial Results published in Radiology, the flagship journal of the Radiological Society of North America (RSNA) HOUSTON, TX, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced the publication of additional positive clinical data in Radiology de</description>
    </item>
  </channel>
</rss>